Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREEZE: Safety of Switching to Tyvaso DPI in PAH
NCT03950739Phase 1Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Sep 2019
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Tyvaso DPI in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Primary endpoints: Change in 6-Minute Walk Distance From Baseline to Week 3, Subject Satisfaction With and Preference for Inhaled Treprostinil Devices at 3 weeks and 2 more. Started Sep 2019; status: completed.
02
Drugs
Tyvaso DPI
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03950739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950739.